The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study evaluating the association of gemcitabine, trastuzumab, and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
 
Eric Assenat
Consulting or Advisory Role - Celgene; Novartis; Pfizer; Sanofi Pasteur
Research Funding - Bayer (Inst); Celgene (Inst); Roche (Inst)
 
Laurent Mineur
No Relationships to Disclose
 
Caroline Mollevi
No Relationships to Disclose
 
Catherine Lombard-Bohas
No Relationships to Disclose
 
Thibault Mazard
Research Funding - Roche (Inst)
 
Emmanuelle Samalin
No Relationships to Disclose
 
Fabienne Portales
No Relationships to Disclose
 
Thomas Walter
Honoraria - Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Ipsen; Novartis
 
Marc Ychou
Consulting or Advisory Role - Bayer/Onyx; Celgene; Novartis; Roche/Genentech